Adcetris
brentuximab vedotin · CD30Three xenograft models from human HL and ALCL cell lines
Elahere: animal efficacy model or human cells?
mirvetuximab soravtansine · FRα
Efficacy evidence
Ovarian cancer xenograft mouse models (single IV dose)
“In vivo, mirvetuximab soravtansine delayed tumor growth and caused tumor regression in several ovarian cancer xenograft mouse models when mice were administered a single IV dose of mirvetuximab soravtansine containing antibody doses as low as 1.2 mg/kg and DM4 dose of 25 µg/kg.”
Why that model
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reviewer's view of the efficacy data
EMA: pharmacology data generally adequate and in line with guidelines
“The pharmacology data is considered in general adequate; the development program is in line with the regulatory guidelines.”
Same question, other ADCs
Besponsa
inotuzumab ozogamicin · CD22Subcutaneous xenograft and systemically disseminated ALL mouse models
Datroway
datopotamab deruxtecan · Trop-2Nude mouse xenografts of human pancreatic cancer, NSCLC and breast cancer
Decnupaz
pivekimab sunirine · CD123Two BPDCN patient-derived xenograft (PDX) models in NSG mice
Emrelis
telisotuzumab vedotin · c-Metc-Met-positive NSCLC cell line-derived and patient-derived xenograft mouse models
Enhertu
fam-trastuzumab deruxtecan · HER2HER2-positive breast cancer xenograft mouse models (e.g., KPL-4 in nude mice)
Kadcyla
ado-trastuzumab emtansine · HER2HER2+ xenografts (BT-474 EI, Calu-3) and MMTV-HER2 transgenic tumor model; growth inhibition in all three at 3 to 31 mg/kg
Mylotarg
gemtuzumab ozogamicin · CD33CD33+ HL-60 leukemia xenograft in mice: >80% tumor growth inhibition
Padcev
enfortumab vedotin · Nectin-4Nectin-4-expressing patient-derived bladder cancer xenografts (AG-B1, AG-B8) in mice: >75% tumor growth inhibition
Polivy
polatuzumab vedotin · CD79bHuman DLBCL and B-cell lymphoma xenografts in mice; in vitro Ramos cytotoxicity
Tivdak
tisotumab vedotin · Tissue factorCervical cancer patient-derived xenograft (PDX) models in mice
Trodelvy
sacituzumab govitecan · Trop-2Mouse xenografts bearing human Trop-2-expressing tumours
Zynlonta
loncastuximab tesirine · CD19CD19-positive human Burkitt lymphoma (Ramos, Daudi) and DLBCL (WSU-DLCL2) xenografts in immunodeficient mice